Infliximab Biosimilar (Remsima (TM)) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F17%3A10338314" target="_blank" >RIV/00216208:11110/17:10338314 - isvavai.cz</a>
Alternative codes found
RIV/00064203:_____/17:10338314 RIV/00064165:_____/17:10338314
Result on the web
<a href="http://dx.doi.org/10.1159/000453343" target="_blank" >http://dx.doi.org/10.1159/000453343</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1159/000453343" target="_blank" >10.1159/000453343</a>
Alternative languages
Result language
angličtina
Original language name
Infliximab Biosimilar (Remsima (TM)) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre
Original language description
Background: The evidence on the efficacy and safety of biosimilar infliximab (IFX) in patients with inflammatory bowel diseases (IBD) is sparse. Methods: Consecutive IBD patients visiting our centre were included. One cohort composed of prospectively followed patients who were switched from original to biosimilar IFX between January and March 2015. The second cohort included retrospectively assessed anti-tumor necrosis factor α-naïve patients who started therapy between January 2015 and January 2016. Disease activity was assessed using standard clinical indices, endoscopic evaluation, and laboratory parameters (blood count, C-reactive protein (CRP) and fecal calprotectin (FC)). Trough levels and anti-drug antibodies (ATIs) were also measured. Patients were evaluated 56 weeks (W56) after switch and at week 14 (W14) and week 46 (W46) in the naïve cohort. Conclusion: Switching of IBD patients from original to biosimilar IFX is effective and safe.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30219 - Gastroenterology and hepatology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Digestive Diseases
ISSN
0257-2753
e-ISSN
—
Volume of the periodical
35
Issue of the periodical within the volume
1-2
Country of publishing house
CH - SWITZERLAND
Number of pages
10
Pages from-to
91-100
UT code for WoS article
000393734900014
EID of the result in the Scopus database
2-s2.0-85011715913